¿Puede rivaroxabán reducir los eventos cardiovasculares en la ERC avanzada? El estudio TRACK comparó rivaroxabán a dosis bajas frente a placebo en pacientes con ERC estadio 4–5 y enfermedad renal en ...

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy. 👑 Is deeper B-cell d...

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Is measured GFR more accurate than eGFR for forecasting adverse outcomes?

Introducing NephJC’s brand new editorial internship class of 2026-2027

For the first time, a podocyte-targeted therapy shows clinical efficacy in FSGS. This week #NephJC covers the phase 2 RCT of BI 764198, an oral TRPC6 inhibitor that lowered proteinuria, preserved eGFR...

Por primera vez, una terapia dirigida al podocito muestra eficacia clínica en GEFyS. Esta semana #NephJC revisa el ECA fase 2 de BI 764198, inhibidor oral de TRPC6, que redujo proteinuria, estabilizó ...

This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterog...

Are you a curious, motivated nephrology fellow or early‑career faculty member with a passion for science communication? NephJC is inviting a small group of talented individuals to join our Editorial I...

ALT: a cartoon character says i 'm so confused in front of a futurama logo